METHYLIN Drug Patent Profile

When do Methylin patents expire, and what generic alternatives are available?

Methylin is a drug marketed by Specgx Llc and is included in three NDAs.

The generic ingredient in METHYLIN is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Methylin

A generic version of METHYLIN was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Summary for METHYLIN

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	4,720
Drug Prices:	Drug price information for METHYLIN
What excipients (inactive ingredients) are in METHYLIN?	METHYLIN excipients list
DailyMed Link:	METHYLIN at DailyMed

See drug prices for METHYLIN

See drug sales revenues for METHYLIN

Recent Clinical Trials for METHYLIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nicoleta Stoicea	Phase 1
Dana-Farber Cancer Institute	Phase 1
Boston Children’s Hospital	Phase 1

See all METHYLIN clinical trials

Pharmacology for METHYLIN

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for METHYLIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
METHYLIN	Oral Solution	methylphenidate hydrochloride	5 mg/5 mL 10 mg/5 mL	021419	1	2010-04-13

US Patents and Regulatory Information for METHYLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-001	Dec 19, 2002	AA	RX	Yes	Yes
Specgx Llc	METHYLIN ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	075629-002	May 9, 2000	AB	RX	No	No
Specgx Llc	METHYLIN	methylphenidate hydrochloride	TABLET, CHEWABLE;ORAL	021475-002	Apr 15, 2003		DISCN	Yes	No
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-002	Dec 19, 2002	AA	RX	Yes	Yes
Specgx Llc	METHYLIN	methylphenidate hydrochloride	TABLET, CHEWABLE;ORAL	021475-001	Apr 15, 2003		DISCN	Yes	No

Expired US Patents for METHYLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-001	Dec 19, 2002	7,691,880
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-002	Dec 19, 2002	7,691,880

International Patents for METHYLIN

See the table below for patents covering METHYLIN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4959335
Austria	526988
European Patent Office	1680144	SOLUTION DE METHYLPHENIDATE ET PROCEDES ASSOCIES D'ADMINISTRATION ET DE PRODUCTION (METHYLPHENIDATE SOLUTION AND ASSOCIATED METHODS OF ADMINISTRATION AND PRODUCTION)
Mexico	PA06003725	SOLUCION DE FENIDATO DE METILO Y METODOS ASOCIADOS DE ADMINISTRACION Y PRODUCCION. (METHYLPHENIDATE SOLUTION AND ASSOCIATED METHODS OF ADMINISTRATION AND PRODUCTION.)
China	1867359	Methylphenidate solution and associated methods of administration and produciton

METHYLIN Market Analysis and Financial Projection

Last updated: April 25, 2026

Market dynamics and financial trajectory for METHYLIN

What is METHYLIN’s market and competitive context?

METHYLIN is the trade name used for methylin (methylphenidate hydrochloride), a CNS stimulant indicated for ADHD (and in some jurisdictions also for narcolepsy). Market dynamics for methylphenidate are dominated by three forces: formulation competitiveness (IR vs ER), payer access, and generic substitution economics.

Key market structure drivers:

• Generic penetration risk is structural. Methylphenidate is widely generic in most markets, which compresses branded pricing power and pushes volume toward low-cost formulations.
• Formulation migration matters. IR products face stronger price pressure than ER options when payers steer patients to covered regimens or prefer fewer daily dosing events.
• Channel concentration affects realized net price. Contracting with pharmacy benefit managers (PBMs) and large national wholesalers drives rebates, formulary placement, and net price outcomes more than list price.

---

How do pricing and reimbursement dynamics typically flow for methylphenidate brands?

For branded methylphenidate products, the financial trajectory usually follows a repeatable pattern driven by managed care contracting:

1. Early phase: higher realized net price if the product launches with favorable formulary placement and patient switching is limited.
2. Mid phase: pressure increases as generics expand assortment and payers apply step edits, prior authorization, or prefer an ER formulary tier.
3. Late phase: brand revenues trend to a small share of total prescription volume unless the product has durable differentiators (true ER performance, differentiated dosing convenience, or strong payer contracts).

Because methylphenidate is a mature therapeutic category, the determinant for net revenue is typically net price and volume retention, not therapeutic novelty.

---

What are the likely financial trajectory shapes (revenue, margins, and cash burn) for a branded Methylphenidate product?

For branded methylphenidate products, financial trajectories commonly show these patterns:

• Revenue trajectory: slope downward as generics capture incremental prescriptions over time, with residual revenue supported by access barriers (PA, step therapy), brand switching inertia, and specific patient tolerability needs.
• Gross margin trajectory: maintained at first via pricing discipline, then compresses as net price declines through rebates and contracting pressure.
• SG&A and payer-facing spend: typically rises as the brand invests more in contracting and formulary retention even as topline declines.
• Net income / operating margin: moves from positive to muted or negative depending on the intensity of ongoing promotional commitments and manufacturing scale efficiency.

A key business implication: in a generic-heavy category, the most material value driver is how long the brand holds net price above the generic competitive trough, not how fast it grows.

---

What market dynamics shift demand for methylphenidate products?

Demand is affected by four operational levers that influence prescriptions and product mix:

• Payer formulary behavior: placement on preferred tiers, restrictions for specific ER/IR products, and PA criteria.
• Patient adherence and dosing convenience: once-daily ER products often benefit when payers and prescribers align around adherence.
• Prescribing guidelines and substitution rules: state-level and plan-level rules that allow pharmacists to substitute generics.
• Supply and manufacturing continuity: stimulants are sensitive to distribution hiccups; sustained supply availability protects market share.

These levers translate into mix shifts (ER vs IR) and share retention outcomes for any branded entry.

---

What does the cash-flow profile usually look like in this category?

Cash-flow dynamics for a methylphenidate brand are typically driven by:

• Working capital and inventory control (stimulants can require disciplined forecasting).
• Rebate accruals that increase as contracts mature and volume mix shifts to cheaper equivalents.
• Manufacturing utilization: revenue erosion without matching capacity reductions can pressure gross profit.

In practical terms, once generic competition intensifies, the financial profile tends to become cash-generative only if the company preserves (1) enough volume at (2) acceptable net price and (3) manufacturing cost per unit.

---

Where does value typically concentrate: IR vs ER?

For methylphenidate brands, the most durable competitive position usually comes from:

• ER products that provide dosing convenience and adherence improvements.
• Patient-specific stability (tolerability, symptom control profile) that supports persistence after payer-driven switching.

If METHYLIN is primarily positioned as an IR alternative, it is more exposed to rapid generic price compression. If it is positioned as an ER option with distinctive dosing performance, the brand has more room for formulary persistence.

---

What are the investment-relevant KPIs for a METHYLIN-style product?

For business planning and valuation, the category translates into measurable KPIs:

KPI	What moves it	Why it matters financially
Net price per prescription	PBM contracting, rebate rates, formulary status	Drives revenue more than list pricing
Prescriptions (volume)	Brand share, substitution, PA/step edits	Determines whether net price erosion is offset by volume
ER/IR mix	Coverage preferences and patient adherence	Affects gross margin via product mix and pricing power
Share retention vs generic equivalents	Conversion policies, switching inertia	Predicts the slope of revenue decline

These KPIs typically offer early signal of whether a branded methylphenidate product is in the “hold net price” window or the “structural erosion” window.

---

How does regulatory and safety scrutiny affect market operations?

Methylphenidate products operate under a persistent regulatory lens due to stimulant misuse risk and controlled-substance compliance. The practical market impacts include:

• Distribution controls and compliance costs
• Monitoring requirements and payer scrutiny
• Supply chain discipline

These factors do not typically change demand elasticity dramatically, but they affect cost-to-serve and operational continuity, which matter when revenues compress.

---

Key Takeaways

• METHYLIN’s market economics are shaped by generic substitution and payer contracting, not by therapeutic differentiation.
• Financial trajectory is typically downward in branded methylphenidate unless the product sustains ER-linked formulary access or preserves net price above the generic trough for long enough.
• The most decision-relevant metrics are net price per prescription, prescription volume, and ER/IR mix, since they jointly determine whether net revenue erosion is offset.
• Operational execution (supply continuity and contract compliance) becomes a bigger driver as category pricing tightens.

---

FAQs

1) What drives profitability for METHYLIN in a mature methylphenidate market?
Net price after rebates and contracting plus manufacturing cost per unit. Volume decline without corresponding unit cost reduction typically compresses operating margin.

2) How do payers usually manage methylphenidate products?
Through preferred tier placement, rebate-backed contracting, and restrictions like prior authorization or step edits that steer patients toward covered options.

3) Does IR versus ER positioning change the financial outlook?
Yes. ER generally faces slower erosion when payers and prescribers align around adherence and coverage, while IR usually experiences faster generic-driven price compression.

4) What is the fastest signal that a branded methylphenidate product is losing revenue momentum?
A sustained drop in realized net price per prescription and share loss toward generic equivalents, often accompanied by unfavorable shift in mix.

5) What operational risks matter most for stimulants like methylphenidate?
Supply chain continuity and distribution compliance. Interruptions and cost-to-serve issues hurt a brand once net revenue is already under pressure.

---

References

[1] U.S. Food and Drug Administration. “Labeling for methylphenidate products.” FDA Drug Labels. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 2026-04-25)
[2] DrugBank. “Methylphenidate.” https://go.drugbank.com/drugs (accessed 2026-04-25)
[3] National Association of Boards of Pharmacy. “Prescriber and pharmacist controlled substances guidance.” https://nabp.pharmacy (accessed 2026-04-25)